StratifAI

🚀 New Nature Portfolio publication from StratifAI! 🚀 We’re pleased to announce that our latest paper, "From whole-slide image to biomarker prediction: end-to-end weakly supervised deep learning in computational pathology", has been published in Nature Protocols! 🎉 The protocol sets the standard for executing computational pathology projects, providing a step-by-step workflow that bridges the gap between clinical researchers and engineers. It is designed to streamline the prediction of biomarkers directly from whole-slide images, making it an invaluable tool for precision oncology. At StratifAI, we’re leading the way in this rapidly evolving field. While this protocol establishes a solid foundation, we’re developing more advanced models and techniques to push the boundaries of what’s possible in computational pathology. Stay tuned for more innovations as we continue to enhance precision oncology through cutting-edge AI technology. 💡 🔗 Read the full protocol here: https://lnkd.in/gpc5BzY6 #AI #DeepLearning #ComputationalPathology #Innovation #CancerResearch #StratifAI

We are thrilled to have StratifAI represented by our co-founders Daniel Truhn and Jakob Nikolas Kather in the session for AI in Clinical Data Analysis at the conference for AI and Electronics for Medicine 2024 in Dresden. 💡 Specifically, our Chief Medical Officer Prof. Dr. med. Daniel Truhn will present on "AI Biomarkers in Oncology: From Research to Practice". The talk covers StratifAI's pioneering work in translating AI-based biomarkers into clinical routine for cancer patient care. 💊 Read more about the conference👇 https://lnkd.in/euuYWRvZ Read more about our latest research 👇 https://lnkd.in/grnKs8VZ https://lnkd.in/gzP-ydwV #precisiononcology #biomarkers #AI #prognostication #outcomes #cancer #pathology #multimodal #innovation

We're thrilled to announce that StratifAI has raised €1.5M in pre-seed funding led by Neulogy Ventures and MultiplexDX International, with participation from Debiopharm, Arve Capital and Christoph Haarburger 🚀 With our diverse team of computer scientists and medical doctors, StratifAI builds the next generation of AI-based biomarkers to improve cancer patient outcomes 🧬 A huge thank you to our amazing investors, mentors and early supporters who believe in our vision. This is only the beginning! Check out the full press release below 👇 https://lnkd.in/gZj5uabH #precisiononcology #biomarkers #AI #cancer

#Biomarkers and #PrecisionOncology   How are AI biomarkers revolutionizing #oncology – from research to clinical practice?   👉 Find out during the talk of Daniel Truhn from StratifAI at #AIEfM24 Session 1 He explores the development and validation of AI-based #biomarkers for cancer diagnosis, prognosis, and treatment response prediction. Hear about the challenges and opportunities in translating these biomarkers into clinical practice – with an emphasis on their potential to improve patient outcomes and personalize cancer care.   The full program including all sessions can be found at: ➡ www.aiefm.de   Technische Universität Dresden Universitätsklinikum Carl Gustav Carus Dresden Else Kröner Fresenius Center for Digital Health Jochen Hampe Gerhard Fettweis #conference #AIEFM24 #AIandElectronicsforMedicine 📸 Daniel Truhn